Cyclosporine in Renal Transplantation

[1]  T. Strom,et al.  Cyclosporine therapy of rat heart allograft recipients and release of interleukins (IL 1, IL 2, IL 3): a role for IL 3 in graft tolerance? , 1984, Journal of immunology.

[2]  T. Beveridge,et al.  LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN THERAPY , 1984, The Lancet.

[3]  T. Starzl,et al.  REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.

[4]  R. Steinman,et al.  Dendritic cells induce T lymphocytes to release B cell-stimulating factors by an interleukin 2-dependent mechanism , 1983, The Journal of experimental medicine.

[5]  W. Paul,et al.  Interleukin 2 induces antigen-reactive T cell lines to secrete BCGF-I , 1983, The Journal of experimental medicine.

[6]  J. Thompson,et al.  A controlled trial of cyclosporine in renal transplantation with conversion to azathioprine and prednisolone after three months. , 1983, Transplantation.

[7]  R. Loertscher,et al.  Persistent elevation of alkaline phosphatase in cyclosporine-treated renal transplant recipients. , 1983, Transplantation.

[8]  D. Katz,et al.  Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Miyawaki,et al.  Cyclosporin A does not prevent expression of Tac antigen, a probable TCGF receptor molecule, on mitogen-stimulated human T cells. , 1983, Journal of immunology.

[10]  G. Klimpel,et al.  Cyclosporin A inhibits the production of gamma interferon (IFNγ), but does not inhibit production of virus-induced IFNα/β , 1983 .

[11]  T. Strom,et al.  Inhibition of the production of a soluble helper mediator by cyclosporin A results in the failure to generate alloreactive cytolytic cells in mixed-lymphocyte culture. , 1983, Clinical immunology and immunopathology.

[12]  T. Strom,et al.  Evidence for the presence of suppressor T lymphocytes in animals treated with cyclosporin A. , 1982, Journal of immunology.

[13]  A. Hess,et al.  Effect of cyclosporin A on human lymphocyte responses in vitro. III. CsA inhibits the production of T lymphocyte growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. , 1982, Journal of immunology.

[14]  G. Klintmalm,et al.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients. , 1981, Transplantation.

[15]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[16]  T. Strom,et al.  CYCLOSPORIN A SPARES SELECTIVELY LYMPHOCYTES WITH DONOR‐SPECIFIC SUPPRESSOR CHARACTERISTICS , 1981, Transplantation.

[17]  M. Omary,et al.  Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Sinclair,et al.  IMMUNOLOGICAL AND PHARMACOLOGICAL MONITORING IN THE CLINICAL USE OF CYCLOSPORIN A , 1981, The Lancet.

[19]  W. Farrar,et al.  Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2. , 1981, Journal of immunology.

[20]  Borel Jf.  Cyclosporin-A--present experimental status. , 1981 .

[21]  S. Mizel,et al.  T-Cell lymphoma model for the analysis of interleukin 1-mediated T-cell activation. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Strom,et al.  Rapid mixed lymphocyte culture testing by analysis of the insulin receptor on alloactivated T lymphocytes: implications for human tissue typing. , 1981, The Journal of clinical investigation.

[23]  A. Waheed,et al.  Production of lymphocyte-activating factor (Interleukin 1) by macrophages activated with colony-stimulating factors. , 1980, Journal of immunology.

[24]  M. Favata,et al.  The functional relationship of the interleukins , 1980, The Journal of experimental medicine.

[25]  T. Strom,et al.  Role of protein and RNA synthesis in the development of insulin binding sites on activated thymus-derived lymphocytes. , 1979, The Journal of biological chemistry.

[26]  D. Dunn,et al.  CYCLOSPORIN A IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM CADAVER DONORS , 1978, The Lancet.

[27]  T. Strom,et al.  Specific insulin binding site on T and B lymphocytes as a marker of cell activation , 1978, Nature.

[28]  R. Brown,et al.  RIFAMPICIN AND CORTISONE REPLACEMENT THERAPY , 1974 .

[29]  A. Richens,et al.  Letter: Thymoxamine and spasticity. , 1974, Lancet.

[30]  T. Bosworth.  Prof. J. B. Buxton , 1954, Nature.

[31]  R. Hardesty,et al.  Cholestasis in heart transplant recipients treated with cyclosporine. , 1983 .

[32]  M. Röllinghoff,et al.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2 , 1981, European journal of immunology.